Furthermore, ATRi is also a viable option to target BRCA‐deficient cancer cells that have acquired resistance to PARPi, by inhibiting the ‘rewired’ HR pathway that is promotes resistance to PARP inhibition (Haynes et al., 2018; Yazinski et al., 2017). Here, PARP1 is linked to cancer.